<DOC>
	<DOCNO>NCT00506285</DOCNO>
	<brief_summary>This study look effectiveness Methylphenidate Transdermal System ( MTS ) treat adult ADHD . MTS receive FDA approval childhood ADHD first trial adult ADHD . Subjects experience two screen visit one baseline visit . Those meet admission criterion enter double-blind phase . This involve two 4-week treatment period one involve use MTS placebo patch . Subjects complete double-blind phase allow enter 180-day , open-label MTS phase design ass long-term effect .</brief_summary>
	<brief_title>Methylphenidate Transdermal System ( MTS ) Treatment Adult ADHD</brief_title>
	<detailed_description>ADHD affect 3 5 % child , persist adolescence 40 70 % child continue adulthood least 50 % affected adolescent . Methylphenidate first medication show effective treatment adult ADHD continue widely use . While extended release formulation represent improvement immediate release version , significant problem remain many patient . In particular , design goal provide medication school hour short time period school . In adult , frequent need much extend duration treatment . MTS new form methylphenidate provide medication transdermal patch delivery system . It even , slowly ascend pharmacokinetic profile . MTS 's stable slowly increase blood level overcome problem note delivery system convenient many patient . It currently approve treatment childhood ADHD , effectiveness safety profile similar form methylphenidate . This study first evaluate effectiveness safety MTS adult ADHD . This double-blind , placebo-controlled , randomize , crossover trial compare MTS placebo patch . The double-blind trial precede enrollment period consist two screen visit follow quickly possible baseline visit . Patients continue meet admission criterion baseline randomize first two 4-week treatment period . We attempt reach high tolerate dose size MTS within 2 week observe response last two week crossover phase . The double-blind period follow 180 day open-treatment , flexible-dose phase design ass long-term effect .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Adults meet DSMIVText Revision criterion ADHD , Utah Criteria ADHD , experience least moderate impairment ( score 4 great CGISeverity Scale ADHD Screening Baseline visit ) enrol . Other criterion include : 1 . Subjects age 18 65 , inclusive ; 2 . Female subject eligible enter participate study : 1 . She nonchildbearing potential ; male sexual partner surgically sterilize ; implant levonorgestrel , injectable progesterone , oral contraceptive ; intrauterine device ( IUD ) ; sexually inactive male partner . 2 . Or agree use double barrier method contraception ( combination physical chemical method ) negative urine pregnancy test screen interview . 3 . Subject must general good health determine medical history , ECG , analysis , judgment study physician , would confirm patient 's good health . 4 . Subjects must read write level sufficient provide write informed consent complete studyrelated material . Subjects eligible inclusion study follow criterion apply : 1 . Subjects current DSMIV Axis I Disorders include Current lifetime history psychosis , current bipolar disorder type I , current Major Depressive Disorder , Current Anxiety Disorder ( unless opinion clinic physician ADHD primary disorder cause disability see patient ) ; 2 . Subjects DSMIV Axis II diagnosis severe would suggest nonresponsiveness pharmacotherapy ADHD noncompliance protocol ; 3 . Subjects risk suicide risk harm others ; 4 . History Substance Dependence accord DSMIV criterion within 3 month screen ; 5 . Subjects currently abuse illegal drug alcohol exclude study ; 6 . Positive urine screen drug abuse screen patient significant history substance use still meet criterion 4 5 . Patients risk substance abuse give urine drug screen ; 7 . Subjects stimulant would represent risk history stimulant abuse , 8 . History uncontrolled hypertension significant cardiovascular disease ; 9 . Any known suspected significant medical psychiatric illness ( e.g. , hepatic renal insufficiency , pulmonary ( asthma , COPD , etc ) , gastrointestinal , endocrine , neurological metabolic disturbance , judgment investigator , may impair interpretation study result constitute significant safety concern context clinical trial ; 10 . Medications , include health food supplement judge investigator likely central nervous system activity ( example , St John 's Wort , gingko leaf , melatonin ) , permit study . If subject take medication prior study entry , must 7 day washout period prior Visit 2 . We ask honest report medication consume visit . In event medication psychoactive property consume , patient counsel regard use prohibit medication ; 11 . Use medication consider acceptable clinical investigator medical monitor 7day period start study ( Day 1 ) ; 12 . Subjects high BMI ( &gt; 38 ) high adipose tissue concentration hip judged clinician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Adult</keyword>
	<keyword>Methylphenidate Transdermal System</keyword>
	<keyword>Daytrana</keyword>
</DOC>